Panelists discuss how disease-modifying therapies for immunoglobulin A (IgA) nephropathy, though initially more expensive ...

Panelists discuss how early diagnosis of immunoglobulin A (IgA) nephropathy enables timely interventions that can ...

Early findings from the SPARTAN phase II trial, presented at the National Kidney Foundation (NKF) Spring Clinical Meeting, ...

Travere Therapeutics stock did suffer a bit of setback last week as the FDA moved back the anticipated decision date on a ...

Over a 35-year journey with a rare kidney disease, Ginger Murphy has become an advocate for her own health and welcomes the ...

IgA nephropathy is a progressive, autoimmune, chronic disease that predominantly affects adults between the ages of 20 and 40, with an annual global incidence of 2.5 cases per 100,000 people. Despite ...

Vera Therapeutics faces a pivotal moment with Phase 3 data expected soon. Depending on the result, the stock may spike or ...